REMICADE(R) RECEIVES APPROVAL IN EUROPEAN UNION FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has granted approval of REMICADE (R) (infliximab) for the treatment of moderate to severe plaque psoriasis. The new indication includes the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or psoralen plus ultraviolet A light (PUVA).

Finanzen (http://finanzen.net/news/news_detail.asp?NewsNr=340251)